Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90

Benzinga · 12/17/2025 13:02
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $75 to $90.